{"id":"gemifloxacin-based-triple-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Tendinopathy"},{"rate":null,"effect":"QT prolongation"}]},"_chembl":{"chemblId":"CHEMBL1200621","moleculeType":"Small molecule","molecularWeight":"485.49"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a fluoroquinolone, gemifloxacin works by binding to and inhibiting bacterial DNA gyrase and topoisomerase IV enzymes, which are essential for bacterial DNA replication, transcription, and repair. When used as part of a triple therapy regimen, gemifloxacin is combined with other antimicrobial agents to enhance efficacy and reduce resistance development. This combination approach is typically employed in treating respiratory tract infections or other serious bacterial infections.","oneSentence":"Gemifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:52.372Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Community-acquired bacterial respiratory tract infections (as part of triple therapy)"}]},"trialDetails":[{"nctId":"NCT02368470","phase":"PHASE3","title":"Randomized Study on Efficacy of Gemifloxacin-based Regimen for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2015-02","conditions":"Helicobacter Pylori Infection","enrollment":252}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8309,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Factive, Rabiet, Pamoxin"],"phase":"phase_3","status":"active","brandName":"Gemifloxacin-based triple therapy","genericName":"Gemifloxacin-based triple therapy","companyName":"Samsung Medical Center","companyId":"samsung-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gemifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription in susceptible bacteria. Used for Community-acquired bacterial respiratory tract infections (as part of triple therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}